Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304021 | 1.00 | NAAA (0.46) | NAAALTB4RLTB4R2PPARAHDAC1 | |
| SCHEMBL345276 | 0.87 | NAAA (0.57) | NAAAPPARAFAAHIDH1 | |
| SCHEMBL345275 | 0.87 | NAAA (0.57) | NAAAPPARAFAAHIDH1 | |
| SCHEMBL6334745 | 0.87 | NAAA (0.57) | NAAAPPARAFAAHIDH1 | |
| SCHEMBL13725779 | 0.87 | NAAA (0.46) | NAAAPPARAHDAC1FAAHIDH1 | |
| SCHEMBL13725782 | 0.87 | NAAA (0.46) | NAAAPPARAHDAC1FAAHIDH1 | |
| SCHEMBL2082871 | 0.87 | NAAA (0.47) | NAAALTB4RLTB4R2PPARAHDAC1 | |
| SCHEMBL2082875 | 0.87 | NAAA (0.47) | NAAALTB4RLTB4R2PPARAHDAC1 | |
| SCHEMBL4521529 | 0.85 | NAAA (0.51) | NAAAHDAC1KMT2AMEN1FAAH | |
| SCHEMBL22800346 | 0.85 | NAAA (0.51) | NAAAHDAC1KMT2AMEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | NAAA 698/4885LTB4R 1393/4885LTB4R2 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.